Grifols (Grifols) EV-to-Revenue

: 3.04 (As of Today)

View and export this data going back to 2006. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Grifols's enterprise value is $16,507 Mil. Grifols's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $5,437 Mil. Therefore, Grifols's EV-to-Revenue for today is 3.04.

The historical rank and industry rank for Grifols's EV-to-Revenue or its related term are showing as below:

GIFLF' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.24 Med: 4.51 Max: 6.18
Current: 3.08

During the past 13 years, the highest EV-to-Revenue of Grifols was 6.18. The lowest was 1.24. And the median was 4.51.

GIFLF's EV-to-Revenue is ranked worse than
61.66% of 1025 companies
in the Drug Manufacturers industry
Industry Median: 2.33 vs GIFLF: 3.08

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-19), Grifols's stock price is $8.46. Grifols's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $8.01. Therefore, Grifols's PS Ratio for today is 1.06.

Grifols EV-to-Revenue Historical Data

The historical data trend for Grifols's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

5.52

4.55

4.03

3.10

2.87

Grifols Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
EV-to-Revenue																1.95	3.10	4.21	4.28	-

Competitive Comparison

For the Drug Manufacturers - General subindustry, Grifols's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grifols EV-to-Revenue Distribution

For the Drug Manufacturers industry and Healthcare sector, Grifols's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Grifols's EV-to-Revenue falls into.

Grifols EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Grifols's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	16507.324	/	5436.835
	=	3.04

Grifols's current Enterprise Value is $16,507 Mil.
Grifols's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5,437 Mil.

Grifols (OTCPK:GIFLF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Grifols's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	8.46	/	8.01
	=	1.06

Grifols's share price for today is $8.46.
Grifols's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.01.

Grifols EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Grifols's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols (Grifols) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (OTCPK:GIFLF) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

GIKLY:USA GIFOF:USA GRFS:USA GRFP:Mexico GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain G0F0:Germany G0F:Germany G0FB:Germany OZTA:Germany OZTA:Germany G0FB:Germany

Address

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.